We are live on ! Find out more
OCRX

Ocera Therapeutics
OCRX

Delisted

OCRX was delisted on the 8th of December, 2017.

21 hedge funds and large institutions have $5.17M invested in Ocera Therapeutics in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.33% less ownership

Funds ownership: 20.45% → 17.12% (-3.3%)

13% less funds holding

Funds holding: 24 → 21 (-3)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

50% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 8

65% less capital inflows, than outflows

Capital inflows: $391K | Capital outflows: $1.12M

Holders
21
Holders Change
-3
Holders Change %
-12.5%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
8
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OCRX Hedge Fund Activity: Q3 2017 in Review

21 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics (OCRX) for Q3 2017, worth a combined $5.17M — down 18% from $6.29M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of OCRX and 2 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 4 added.

The largest buyer was Hikari Power, adding an estimated $322K. The largest seller was VHCP Management II, cutting an estimated $794K.

  • 21 institutional investors held Ocera Therapeutics (OCRX) as of Q3 2017, down from 24 in Q2 2017.
  • Funds reported $5.17M of Ocera Therapeutics stock for Q3 2017, down 18% quarter-over-quarter.
  • 2 funds opened new Ocera Therapeutics positions in Q3 2017 and 4 closed out, a net change of -2 holders.
  • The largest Ocera Therapeutics buyer in Q3 2017 was Hikari Power, an estimated $322K added.
  • The largest Ocera Therapeutics seller in Q3 2017 was VHCP Management II, an estimated $794K sold.

Based on aggregated 13F filings for Q3 2017.